Iran Press/ Iran News: "Alireza Bigleri," the head of the Pasteur Institute of Iran, told Iran Press on Friday: "The third phase of the clinical trial of the Pastocovac vaccine was carried out in a very favorable level in Iran, and with the implementation of this study plan, important aspects of this vaccine were identified."
"The vaccine has been shown to be effective and safe against COVID-19," Bigleri said.
The head of the Pasteur Institute of Iran (IPI) also said: "The article obtained from the results of the study of the third phase of the Pastecovac corona vaccine trial in Iran has been accepted in a journal with very high scientific and international prestige and will be published soon."
Pastecovac is a recombinant vaccine. The first and second phases of the clinical trial of this vaccine were co-produced by the Cuban Finlay Institute and the Pasteur Institute of Iran in Cuba.
In the first phase, 40 volunteers, and in the second phase, 920 volunteers were present. In these two phases, the safety of the vaccine and determining the appropriate dose were evaluated.
The third phase of the clinical trial of this vaccine was performed in Iran and Cuba with 44,000 volunteers in Cuba and 24,000 volunteers in Iran.
Pastecovac Plus has received an emergency use license from Iran's Food and Drug Administration.
205
Read More:
PastoCoVac; safest vaccine in the world: Pasteur Institute head
